Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287675 · ClinicalTrials.gov registry record · Phase 4
Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
A Phase 4 study of Breast Cancer, sponsored by Kettering Health Network.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02287675: Completed Phase 4 study of Breast Cancer, sponsored by Kettering Health Network.
NCT02287675 is a Phase 4 study of Breast Cancer that has completed, run by Kettering Health Network. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02287675, a Phase 4 study of Breast Cancer, has completed, sponsored by Kettering Health Network.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the kinetics and efficacy of two functionally different diagnostic agents, Lymphoseek (CD206 receptor targeted) and 99mTc-Sulfur Colloid (SC) (Sulfur Colloid non-specific mapping agent) in intraoperative lymphatic mapping (ILM) and Sentinel Lymph Node Biopsy (SLNB).
Conditions Studied
Interventions
- DRUG Lymphoseek
- DRUG Sulfur Colloid
Study Locations (1)
Ohio
- Kettering Medical Center - Kettering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287675
The ClinicalTrials.gov registry entry for NCT02287675 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Kettering Health Network, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lymphoseek is the first listed.
NCT02287675 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02287675 about?
NCT02287675 is a clinical study titled "Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer". To compare the kinetics and efficacy of two functionally different diagnostic agents, Lymphoseek (CD206 receptor targeted) and 99mTc-Sulfur Colloid (SC) (Sulfur Colloid non-specific mapping agent) in intraoperative lymphatic mapping (ILM) and Sentinel Lymph Node Biopsy (SLNB).
What is the current status of trial NCT02287675?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-01-19. Estimated completion is 2017-08-31.
What conditions does trial NCT02287675 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02287675?
The interventions under investigation include: Lymphoseek (DRUG), Sulfur Colloid (DRUG).
Who is sponsoring clinical trial NCT02287675?
This trial is sponsored by Kettering Health Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287675 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.